Effects ofYiqi Shuxin Pills on Coronary Flow Reserve of Patients with Acute Coronary Syndrome in Coronary Angiography
10.3969/j.issn.1005-5304.2016.05.009
- VernacularTitle:益气舒心丸对急性冠脉综合征患者冠状动脉造影术中冠脉血流储备的影响
- Author:
Huayun ZHAO
;
Wenhui WANG
;
Weiqiang CHEN
;
Honglei YANG
;
Zhimin LUO
;
Shihua CAI
- Publication Type:Journal Article
- Keywords:
Yiqi Shuxin Pills;
acute coronary syndrome;
coronary angiography;
coronary flow reserve;
qi-deficiency syndrome;
blood-stasis syndrome
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2016;23(5):33-36
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effects ofYiqi Shuxin Pills on the coronary flow reserve (CFR) of patients with acute coronary syndrome (ACS) in the coronary angiography (CAG); To discuss its relevant mechanism of action.Methods Totally 101 patients with ACS were divided into control group (49 cases) and treatment group (52 cases). Patients in the treatment group were treated with western therapy andYiqi Shuxin Pills, while patients in the control group were treated with western therapy only. After treated for 6 months, CAG was reviewed to compare the CFR in both groups before and after the treatment. The blood-stasis syndrome and qi-deficiency syndrome scores and the level of NO, ET-1, hs-CRP, sVCAM-1, P-selectin in blood of both groups before and after the treatment were observed.Results The blood-stasis syndrome and qi-deficiency syndrome scores in the treatment group were significantly lower than those in the control group (P<0.01); The levels of ET-1, hs-CRP, sVCAM-1, P-selectin were obviously reduced and NO obviously increased in treatment group than those of control group (P<0.05). The CFR in the treatment group was significantly better than that of control group, with statistical significance (P<0.05). ConclusionYiqi Shuxin Pills can improve the state of blood-stasis syndrome and qi-deficiency syndrome, improve vascular endothelial function, relieve inflammatory reaction, lower the expression of platelet, stabilize atherosclerotic plaque of coronary artery, and then improve the CFR of ACS patients in CAG.
